skip to content

At-a-Glance

Issue No. 6 | March 24, 2017

News and Features

Adult and Adolescent Opportunistic Infections Guidelines Updated

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents were updated on March 13, 2017. In this revision:

  1. Table 5. Significant Pharmacokinetic Interactions for Drugs Used to Treat or Prevent Opportunistic Infections was updated with the following key modifications:
    • Antiretroviral drugs were removed from this table; clinicians should refer to the Adult and Adolescent Antiretroviral Treatment Guidelines' Drug Interaction section to review potential interactions and recommendations for when OI drugs are used concomitantly with certain antiretroviral drugs.
    • Drugs used for the treatment of hepatitis C virus infection and malaria were added to this table.
  2. Table 6. Common or Serious Adverse Reactions Associated With Drugs Used for Preventing or Treating Opportunistic Infections was updated with the inclusion of adverse effects associated with drugs for the treatment of hepatitis C virus infection and malaria.

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Welcomes New Panel Members

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Council) is pleased to welcome the following 3 new scientific members and 2 new community members to the Panel who will begin a 4-year term starting in May 2017.

Scientific Members:

  • Susan Cu-Uvin, MD (Brown University, Providence, RI)
  • Edward Gardner, MD (Denver Public Health and University of Colorado, Denver, CO)
  • Serena Spudich, MD, MA (Yale University, New Haven, CT)

Community Members:

  • Danielle Campbell, MPH (University of California-Los Angeles, Los Angeles, CA)
  • Steven Vargas (Association for the Advancement of Mexican Americans, Houston, TX)

The Panel would like to express our gratitude and appreciation to the following outgoing members for the many years of dedication and contributions in the development of these guidelines:

  • Victoria Cargill, MD, MSCE (National Institutes of Health, Bethesda, MD)
  • Deborah Cohan, MD (University of California-San Francisco, San Francisco, CA)
  • Danielle Houston (National Minority AIDS Council, Washington, DC)
  • Michael Hughes, PhD (Harvard School of Public Health, Boston, MA)
  • Bill Kapogiannis, MD (National Institutes of Health, Bethesda, MD)
  • Daniel Kuritzkes, MD (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA)
  • Bret Rudy, MD (New York University, New York, NY) 
  • Mark Sulkowski, MD (Johns Hopkins University, Baltimore, MD)

Refining the NIH HIV Research Enterprise for the Next Decade

NIH recently launched a 3-year process to refine its science-driven HIV research enterprise for the coming decade. Input from the research community is crucial to help NIH define the questions that will shape NIH HIV clinical research through 2027. Visit the NIAID Refining the HIV Research Enterprise webpage to learn more about the process and to submit questions or comments.

Monkeys Suppress HIV-Like Virus for Extended Period After Dual-Antibody Treatment

“Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.”

To learn more, read the NIAID press release.